These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. Erice A; Chou S; Biron KK; Stanat SC; Balfour HH; Jordan MC N Engl J Med; 1989 Feb; 320(5):289-93. PubMed ID: 2536135 [No Abstract] [Full Text] [Related]
24. Editorial commentary: Use of valganciclovir for prevention and treatment of cytomegalovirus disease. Snydman DR Clin Infect Dis; 2008 Jan; 46(1):28-9. PubMed ID: 18171209 [No Abstract] [Full Text] [Related]
25. Drug resistance in cytomegalovirus: current knowledge and implications for patient management. J Acquir Immune Defic Syndr Hum Retrovirol; 1996; 12 Suppl 1():S1-22. PubMed ID: 8680897 [No Abstract] [Full Text] [Related]
26. [Strains of ganciclovir-resistant cytomegalovirus]. Calicó I; García E; Cortés A; Gavaldá J; Roman A; Valle I Enferm Infecc Microbiol Clin; 1999; 17(7):330-4. PubMed ID: 10535184 [TBL] [Abstract][Full Text] [Related]
27. Treatment of cytomegalovirus infections in renal transplant recipients with 9-(1,3-dihydroxy-2-propoxymethyl) guanine. Cantarovich M; Hiesse C; Lantz O; Fassi-Fihri S; Charpentier B; Fries D Transplantation; 1988 Jun; 45(6):1139-41. PubMed ID: 2837848 [No Abstract] [Full Text] [Related]
28. [Acyclovir and ganciclovir in the treatment of malignant hematological diseases]. Zhou X; Gan X; Meng P Zhonghua Nei Ke Za Zhi; 1997 May; 36(5):349-51. PubMed ID: 10374276 [No Abstract] [Full Text] [Related]
29. Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient. Hantz S; Michel D; Fillet AM; Guigonis V; Champier G; Mazeron MC; Bensman A; Denis F; Mertens T; Dehee A; Alain S Antimicrob Agents Chemother; 2005 Apr; 49(4):1580-3. PubMed ID: 15793144 [TBL] [Abstract][Full Text] [Related]
30. Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Kern ER Transplant Proc; 1991 Jun; 23(3 Suppl 3):152-5, discussion 155. PubMed ID: 1648821 [No Abstract] [Full Text] [Related]
31. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Winston DJ; Busuttil RW Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129 [TBL] [Abstract][Full Text] [Related]
32. Long-term care after hematopoietic-cell transplantation in adults. Boeckh M; Nichols WG; Marr KA N Engl J Med; 2002 Nov; 347(20):1625-6; author reply 1625-6. PubMed ID: 12432056 [No Abstract] [Full Text] [Related]
33. [Gastrointestinal cytomegalovirus infections in organ transplant patients]. Péter A; Telkes G; Varga M; Járay J Orv Hetil; 2008 Dec; 149(52):2463-70. PubMed ID: 19087914 [TBL] [Abstract][Full Text] [Related]
34. [Valganciclovir. Oral treatment of Cytomegalovirus infections]. Kroes AC Ned Tijdschr Geneeskd; 2004 Jun; 148(25):1236-8. PubMed ID: 15301386 [TBL] [Abstract][Full Text] [Related]
35. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]